1. New rhodol-sulforaphane conjugates as innovative isothiocyanate-based cytotoxic agents for cancer cells.
- Author
-
Milelli A, Catanzaro E, Greco G, Calcabrini C, Turrini E, Maffei F, Burattini S, Guardigni M, Sissi C, Schnekenburger M, Diederich M, Sestili P, and Fimognari C
- Subjects
- Humans, DNA Damage drug effects, Molecular Structure, Structure-Activity Relationship, Apoptosis drug effects, Dose-Response Relationship, Drug, Cell Proliferation drug effects, Cell Line, Tumor, Isothiocyanates chemistry, Isothiocyanates pharmacology, Isothiocyanates chemical synthesis, Sulfoxides chemistry, Sulfoxides pharmacology, Sulfoxides chemical synthesis, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Drug Screening Assays, Antitumor
- Abstract
In search of semisynthetic derivatives with increased antitumor activity, we condensed sulforaphane (SFR) with rhodol, a fluorophore platform capable of modifying the intracellular trafficking and pharmacokinetics of the linked molecules. The two tested derivatives, namely MG28 and MG46, showed a far higher, as compared to SFR, cytotoxicity toward cancer cells. Apoptotic cell death was preceded by the extensive generation of DNA lesions, which were repaired relatively slowly and caused formation of micronuclei. Unlike SFR, rhodol-SFR conjugates' DNA lesions resulted from direct interactions with nuclear DNA. Overall, MG28 and MG46 exhibit a remarkable cytotoxic effect, which is the likely consequence of their direct and intense DNA damaging activity, i.e., a novel and peculiar mechanism arising from the conjugation of the parental rhodol and SFR. Considering that a wide number of clinically used drugs kill cancer cells by inducing DNA damage, MG could represent a new and promising chance in antitumor chemotherapy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF